Be Biopharma unveils promising preclinical results for hypophosphatasia treatment using engineered B cell medicines
Be Biopharma, Inc. has presented groundbreaking preclinical findings that underscore the potential of Engineered B Cell Medicines (BCMs) as a novel therapeutic avenue for Hypophosphatasia ... Read More
Exonics Therapeutics receives $5m seed funding to advance Duchenne Muscular Dystrophy therapy
Exonics Therapeutics, a biotechnology firm based in Boston, Massachusetts, has secured $5 million in seed funding from CureDuchenne Ventures, a subsidiary of the nonprofit Duchenne ... Read More